{"product_id":"ss-31-50mg-3ml-elamipretide-research-peptide-uk","title":"SS-31 50mg 3ml Elamipretide Research Peptide UK","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFor research use only. Not for human consumption.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSS-31 (Elamipretide \/ MTP-131 \/ Bendavia) — 50mg | Pre-Mixed 3ml Vial | ≥99% Purity | COA Verified | UK Dispatch\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSS-31, also known as Elamipretide (development codes MTP-131, Bendavia, SBT-272), is a synthetic aromatic-cationic tetrapeptide specifically designed to selectively target and accumulate within the inner mitochondrial membrane. First characterised by Szeto and Schiller, SS-31 is among the most clinically investigated mitochondria-targeted peptides, with completed Phase I–III trials in Barth syndrome, heart failure, primary mitochondrial myopathy, renal artery stenosis, and age-related macular degeneration. It received FDA approval in September 2025 under the brand name Forzinity for the treatment of Barth syndrome — making it one of the few research peptides to achieve approved medicine status, underscoring the depth of its clinical evidence base.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThis listing features a \u003cstrong\u003epre-mixed, ready-to-use 3ml vial\u003c\/strong\u003e containing \u003cstrong\u003e50mg of research-grade SS-31 (Elamipretide)\u003c\/strong\u003e — providing consistent, laboratory-ready concentration without manual reconstitution.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism of Action in Research\u003c\/strong\u003e SS-31 exerts its effects primarily through direct binding to \u003cstrong\u003ecardiolipin\u003c\/strong\u003e — a unique phospholipid found exclusively in the inner mitochondrial membrane, essential for electron transport chain function and mitochondrial membrane integrity. By stabilising cardiolipin, SS-31 is studied for its ability to:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003ePrevent cytochrome c peroxidase activity and reduce mitochondrial ROS generation\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eRestore electron transport chain efficiency and ATP synthesis capacity\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMaintain inner mitochondrial membrane potential under conditions of oxidative stress\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eProtect against mitochondrial swelling and membrane permeabilisation associated with cell death pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eKey Research Areas\u003c\/strong\u003e SS-31 is one of the most broadly studied mitochondria-targeted peptides in preclinical research, with significant interest across multiple disciplines:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMitochondrial dysfunction \u0026amp; cardiolipin protection\u003c\/strong\u003e — the defining mechanism: SS-31 selectively binds and stabilises cardiolipin in the inner mitochondrial membrane, preserving electron transport chain architecture under oxidative stress\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCardiovascular research\u003c\/strong\u003e — studied in heart failure models; preclinical data demonstrate improvements in left ventricular function, mitochondrial energetics, and cardiac output in advanced heart failure animal models\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAge-related muscle decline \u0026amp; sarcopenia\u003c\/strong\u003e — in aged mouse models, SS-31 reversed age-related decline in mitochondrial ATP production, restored redox homeostasis, and significantly improved skeletal muscle mass, fatigue resistance, and treadmill endurance\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eNeurodegenerative disease models\u003c\/strong\u003e — studied in models of Alzheimer's, Parkinson's, and LPS-induced neuroinflammation; shown to reduce mitochondrial dysfunction, oxidative stress, neural apoptosis, and dendritic spine loss in the hippocampus\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eRenal protection\u003c\/strong\u003e — clinical pilot data demonstrate attenuated post-procedural hypoxia and improved renal blood flow when used adjunctively; preclinical models show protection in ischaemia-reperfusion injury and diabetic nephropathy\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMetabolic \u0026amp; inflammatory pathways\u003c\/strong\u003e — modulation of SIRT1, NF-κB, and oxidative stress markers in type 2 diabetes models; increased glutathione redox ratio and reversal of cysteine S-glutathionylation in aged skeletal muscle\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMitochondrial myopathy \u0026amp; Barth syndrome\u003c\/strong\u003e — the compound with the longest clinical track record in primary mitochondrial disease; FDA approved September 2025 for Barth syndrome\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAge-related macular degeneration\u003c\/strong\u003e — Phase 1 clinical trial demonstrated safety and tolerability via subcutaneous administration in AMD patients with high-risk drusen\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eProduct Specifications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 736992-21-5\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSequence:\u003c\/strong\u003e D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH₂ (D-Arg-Dmt-Lys-Phe-NH₂)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eOther Names:\u003c\/strong\u003e Elamipretide, MTP-131, Bendavia, SBT-272, Szeto-Schiller-31, Forzinity (brand)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₃₂H₄₉N₉O₅\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 639.8 g\/mol\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePubChem CID:\u003c\/strong\u003e 11764719\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAmino Acids:\u003c\/strong\u003e 4 (tetrapeptide)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eQuantity:\u003c\/strong\u003e 50mg per vial\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eVolume:\u003c\/strong\u003e 3ml (pre-mixed)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥99% (HPLC verified)\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Pre-mixed solution\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAppearance:\u003c\/strong\u003e Clear, colourless to pale solution\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSolubility:\u003c\/strong\u003e Water soluble; highly cell-permeable, rapidly accumulates in mitochondria independent of membrane potential\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Refrigerate at 2–8°C once mixed. Do not freeze reconstituted solution. Protect from light and UV exposure. Avoid repeated freeze-thaw cycles. Lyophilised (unmixed) stable below −18°C long-term.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eShelf life (pre-mixed):\u003c\/strong\u003e Use within 21–28 days. Inspect before use — discard if discoloured or particulate present.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eDispatch:\u003c\/strong\u003e Fast UK dispatch. Orders placed before 2pm dispatched same working day.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eConcentration\u003c\/strong\u003e At 50mg in 3ml: \u003cstrong\u003econcentration = 16.67mg\/ml (16,667mcg\/ml)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCOA Available:\u003c\/strong\u003e Every batch independently third-party tested. Certificate of Analysis available on our Lab Reports page before ordering.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cem\u003eAll products sold by Ultra Peptides are strictly for laboratory and in-vitro research purposes only. Not intended for human or veterinary use outside of approved clinical or research contexts. Not approved by the MHRA for any cosmetic, therapeutic, or general medical application in the UK. By purchasing this product you confirm your intended use is for legitimate scientific research conducted in a controlled laboratory setting.\u003c\/em\u003e\u003c\/p\u003e","brand":"Ultra Peptides","offers":[{"title":"Default Title","offer_id":47496674705602,"sku":null,"price":49.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0742\/4481\/7090\/files\/SS-31---50mg---3ml.png?v=1776890888","url":"https:\/\/ultrapeptides.co.uk\/products\/ss-31-50mg-3ml-elamipretide-research-peptide-uk","provider":"Ultra Peptides","version":"1.0","type":"link"}